Navigation Links
Trius' Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
Date:9/12/2009

SAN DIEGO, Sept. 12 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of torezolid at the low 200 mg dose against methicillin-sensitive and methicillin-resistant bacteria in patients with severe complicated skin and skin structure infections (cSSSI). In vitro studies presented at ICAAC highlight the potency of torezolid against linezolid-resistant MRSA and cfr-mediated resistant bacteria.

"The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against bacterial strains proven to be resistant to linezolid," said Philippe Prokocimer, M.D., chief medical officer at Trius." There is an urgent need for more potent antibiotics like torezolid with different mechanisms of action that can circumvent drug resistance pathways."

ICAAC data presentations are as follows:

Saturday, September 12

(Poster Session 024, 11:30 am - 1:30 pm)

  • L1-335/355: Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI)

(Poster Session 004, 11:30 am - 1:30 pm)

  • B-050/52: Comparative Efficacy of TR-701, Vancomycin (Vanco), and Daptomycin (Dapto) in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Endocarditis

Sunday, September 13

(Poster Session 082a, 11:15 am - 1:15 pm)

  • E-808/275: Activity of Torezolid against linezolid-resistant MRSA strains with cfr gene mediated resistance
  • E-807/274: Comparative Activity of TR-700 Against Staphylococci Blood Isolates Collected in Spain
  • E-809/276: In Vitro Activity of Torezolid (TR-700) versus Linezolid against Chlamydia species

Monday, September 14

(Poster Session 155, 11:15 am - 1:15 pm)

  • C1-1346/84: Unexpectedly low cost of fitness associated with acquisition of the cfr resistance gene
  • C1-1364b/104: Genetic Environment and Instability of cfr in MRSA CM05
  • C1-1364a/103: In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial
  • C1-1349/87: Mutations in Ribosomal Protein L3 are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin

Tuesday, September 15

(Poster Session 226, 9:00 am - 11:00 am)

  • A1-1939/12: Compararative Pharmacodynamics of a Novel Oxazolidinone, TR-701, Against S. aureus in a Neutropenic Murine Pneumonia Infection Model
  • A1-1935/8: Defining the Impact of Granulocytes (G) on the Kill of Methicillin-Resistant Staphylococcus aureus (MRSA) by the New Oxazolidanone Prodrug TR-701
  • A1-1947/20: Evaluation of Tissue Distribution of TR-700 in Healthy Volunteers, Using Microdialysis
  • A1-1934/7: Torezolid (TR-700), a novel methyltetrazolyl-oxazolidinone, accumulates markedly within human THP-1 macrophages and shows activity towards intraphagocytic Legionella pneumophila: comparison with linezolid

Copies of these posters will be available on the Trius Web site following the ICAAC meeting.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently marketed antibacterial drug of the oxazolidinone class. Trius' pipeline includes two preclinical programs with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
2. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
3. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Trius Doses First Patient in Antibacterial Phase 2 Trial
6. PacificGMP Completes GMP Product Fill for Trius Therapeutics
7. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
8. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
9. NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
10. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
11. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):